NCT05749042 is a Phase 2 clinical trial of Sintilimab in Oral Cavity Squamous Cell Carcinoma, sponsored by Xin-Hua Xu.

Who is sponsoring NCT05749042?

NCT05749042 is sponsored by Xin-Hua Xu.

What drugs are being tested in NCT05749042?

Interventions in NCT05749042: Sintilimab, Radiotherapy.

What condition does NCT05749042 study?

NCT05749042 studies Oral Cavity Squamous Cell Carcinoma.

Is NCT05749042 still recruiting?

NCT05749042 is currently status unknown. Last updated 1 March 2023.

Last reviewed 2023-03-01 · How we verify

NCT05749042

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Status unknown Phase 2 Last updated 1 March 2023

What this trial tests

Phase 2 trial testing Sintilimab in Oral Cavity Squamous Cell Carcinoma in 70 participants. Status unknown.

Timeline

18 January 2023

Primary endpoint
18 January 2025

18 January 2025

Quick facts

Lead sponsor	Xin-Hua Xu
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	18 January 2023
Primary completion	18 January 2025
Estimated completion	18 January 2025
Sites	1 location across China

Drugs / interventions tested

Sintilimab — full drug profile →
Radiotherapy — full drug profile →

Conditions studied

Oral Cavity Squamous Cell Carcinoma — all drugs for Oral Cavity Squamous Cell Carcinoma →

Sponsor

Xin-Hua Xu — full company profile →

Who can join

Adults 18 to 75, any sex, with Oral Cavity Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the efficacy and safety of concurrent chemoradiotherapy based of cisplatin with sintilimab as first-line therapy for patients with advanced oral cavity squamous cell carcinoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sintilimab

Trials testing the same drug.

NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting

Other recruiting trials for Oral Cavity Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
NCT07121595 — Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cel · Phase 2 · recruiting
NCT06947668 — Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel · recruiting
NCT06662058 — Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi · NA · recruiting
NCT06532279 — Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient · Phase 2 · recruiting

Other Xin-Hua Xu trials

Trials by the same sponsor.

NCT06467500 — A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monoth · Phase 2 · recruiting
NCT06029829 — The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution. · Phase 2 · unknown
NCT05792995 — Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes · Phase 2 · completed
NCT04411706 — A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma · Phase 2 · unknown
NCT04367909 — A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05749042 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xin-Hua Xu
Last refreshed: 1 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05749042.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing